Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk

Diabetes, Obesity and Metabolism

Volumn 14, Issue 1, 2012, Pages 30-39

  Stalenhoef, A F H ^a   Davidson, M H ^b   Robinson, J G ^c   Burgess, T ^d   Duttlinger Maddux, R ^e   Kallend, D ^e   Goldberg, A C ^f   Bays, H ^g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

Cardiovascular disease; Clinical trial; Dyslipidaemia; Phase I II study; Randomized trial; Type 2 diabetes

Indexed keywords

ATORVASTATIN; DALCETRAPIB; PRAVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ANGINA PECTORIS; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR RISK; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FLATULENCE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART PALPITATION; HEMATOLOGY; HIATUS HERNIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LYMPHADENOPATHY; METABOLIC SYNDROME X; NEUROCYSTICERCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; POST HOC ANALYSIS; RECTUM CANCER; RHINOPHARYNGITIS; SIDE EFFECT; SINUS TACHYCARDIA; SQUAMOUS CELL CARCINOMA; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

EID: 83655167026     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01485.x     Document Type: Article

References (25)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
3. Almdal T, Scharling H, Jensen J, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13 000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-1426.
4. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001; 161: 1717-1723.
5. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292: 2495-2499.
6. Neeli H, Gadi R, Rader DJ. Managing diabetic dyslipidemia: beyond statin therapy. Curr Diab Rep 2009; 9: 11-17.
7. Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008; 5: 319-335.
8. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
9. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-2519.
10. Keech AC, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
11. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
12. American Diabetes Association. Standards in medical care in diabetes-2010. Diabetes Care 2010; 33: S11-S61.
13. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
14. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesterol ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51: 3443-3454.
15. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105: 2159-2165.
16. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005; 95: 1085-1088.
17. Stein EA, Stroes ESG, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009; 104: 82-91.
18. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010; 31: 480-488.
19. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
20. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154: 1465-1473.
21. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143-3421.
22. Alberti KGMM, Zimmet P, Shaw JA. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
23. Stroes ES, Kastelein JJ, Bénardeau A, et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br J Pharmacol 2009; 158: 1763-1770.
24. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
25. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158: 896-901.